ホーム › びまん性大細胞型B細胞リンパ腫 › ミシガン州
ミシガン州におけるびまん性大細胞型B細胞リンパ腫の臨床試験
ミシガン州内の拠点で、びまん性大細胞型B細胞リンパ腫に関する15件の研究が参加者を募集しています。
ミシガン州内の都市
公式研究テキスト（英語）
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- OSF Saint Francis Hospital and Medical Group, Escanaba
- Schoolcraft Memorial Hospital, Manistique
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Corewell Health ( Site 0162), Grand Rapids
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05139017A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Henry Ford Health System, Detroit
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545), Ann Arbor
- Karmanos Cancer Institute ( Site 0174), Detroit
- Corewell Health ( Site 0130), Grand Rapids
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Michigan Comprehensive Cancer Center, Ann Arbor
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- University of Michigan, Ann Arbor
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Corewell Health, Grand Rapids
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Corewell Health, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07424833DALY II USA/ MB-CART2019.1 for DLBCL
- University of Michigan, Ann Arbor
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- Karmanos Cancer Center (Wayne State University), Detroit
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT05852717Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Bronson Battle Creek, Battle Creek
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- 他13件
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- 他12件
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05890352ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。